Induced parturition in dairy cattle: A comparison of a corticoid (flumethasone) and a prostaglandin (PGF2α) in different age groups

Kordts, E.; Jöchle, W.

doi:10.1016/0093-691x(75)90001-1

Cited by 22 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[130][131][132][133][134][135][136][137] Corticosteroids (dexamethasone 20-30 mg IM or flumethasone 10 mg IM) or prostaglandins F 2a (cloprostenol 500 mg IM or dinoprost 25 mg IM)) are used either alone or as a combination treatment. [131][132][133][134][135][136] These protocols have the potential to enhance viability of calves delivered preterm but should not be administered more than 2 weeks before anticipated calving date for the classic indications. In cows that are clone recipients, current recommendations are to administer treatments up to 36 hours before timed C-section at term.…”

Section: Surfactant Studies In Large Animalsmentioning

confidence: 99%

Role of Lung Surfactant in Respiratory Disease: Current Knowledge in Large Animal Medicine

Christmann

Buechner-Maxwell

Witonsky

et al. 2009

Veterinary Internal Medicne

View full text Add to dashboard Cite

Lung surfactant is produced by type II alveolar cells as a mixture of phospholipids, surfactant proteins, and neutral lipids. Surfactant lowers alveolar surface tension and is crucial for the prevention of alveolar collapse. In addition, surfactant contributes to smaller airway patency and improves mucociliary clearance. Surfactant-specific proteins are part of the innate immune defense mechanisms of the lung. Lung surfactant alterations have been described in a number of respiratory diseases. Surfactant deficiency (quantitative deficit of surfactant) in premature animals causes neonatal respiratory distress syndrome. Surfactant dysfunction (qualitative changes in surfactant) has been implicated in the pathophysiology of acute respiratory distress syndrome and asthma. Analysis of surfactant from amniotic fluid allows assessment of fetal lung maturity (FLM) in the human fetus and exogenous surfactant replacement therapy is part of the standard care in premature human infants. In contrast to human medicine, use and success of FLM testing or surfactant replacement therapy remain limited in veterinary medicine. Lung surfactant has been studied in large animal models of human disease. However, only a few reports exist on lung surfactant alterations in naturally occurring respiratory disease in large animals. This article gives a general review on the role of lung surfactant in respiratory disease followed by an overview of our current knowledge on surfactant in large animal veterinary medicine.

show abstract